Xanodyne Pharmaceuticals, Inc.
Investment Company
| Name | Xanodyne Pharmaceuticals, Inc. |
|---|---|
| Sektor | Gesundheitswesen |
| Land | United States |
| Erstes Inv. |
2005 |
| Geschäftsfokus | Specialty pharmaceutical company focusing on innovative products in the therapeutic areas of women's health and pain management |
| Kontakt |
7300 Turfway Road, Suite 300
Florence KY 41042 |
Xanodyne Pharmaceuticals, Inc., a specialty pharmaceutical company focusing on innovative products in the therapeutic areas of women's health and pain management, today announced that the Bankruptcy Court for the District of Delaware has approved its bid to acquire the pharmaceutical assets of aaiPharma (PINK SHEET: AAIIQ). The deal terms included $209.25 million cash and additional non-cash consideration.
Weiter >>Presse
Apax Partners sells Spectrum Holding Company, Inc. for $230 million
Funds advised by Apax Partners today announced the sale of Spectrum Holding Company, Inc. to Welsh, Carson, Anderson & Stowe for $230 million.
Apax Partners’ Funds acquire Healthcare leader Marken
A consortium comprising funds advised by Apax Partners and company management has reached agreement to acquire Marken, a company specialising in clinical trial logistics, for an undisclosed sum from Intermediate Capital Group.
Apax Partners completes acquisition of TriZetto Group
The TriZetto Group, Inc. and Apax Partners announced today the closing of the merger pursuant to which funds advised by Apax Partners, together with minority investors BlueCross BlueShield of Tennessee and The Regence Group, acquired all of TriZetto’s common stock for $22 cash per share.